PROF. JUDY M. DELP, PHD on D’OXYVA’s Efficacy

Share on facebook
Share on twitter
Share on linkedin
Share on pinterest
Share on reddit
Share on tumblr
Share on telegram
Share on whatsapp

Toriyama et al. studied the effect of CO2 bathing in 83 limbs with critical ischemia and achieved limb salvage in 83% without surgery. They concluded that peripheral vasodilation from CObathing resulted from an increased parasympathetic and decreased sympathetic activity. Application of transdermal COproduces a remote vasodilation that may be mediated through release of a circulating humoral agent. 

Recently, studies have documented that episodes of brief, non-damaging ischemia occurring in a tissue can induce systemic protection against ischemia-reperfusion injury in a remote organ. This phenomenon, termed remote ischemic conditioning, has been demonstrated to confer protection against ischemic events in the myocardium, brain, and kidney. Although shown to be effective in various clinical and preclinical models, the mechanism(s) of remote protection have not been clearly identified. Both neural and humoral mechanisms have been proposed to contribute to the protection against ischemic damage afforded by remote ischemic conditioning. Basalay et al. have shown that when remote ischemic conditioning is applied before induction of myocardial ischemia, sensory nerves and recruitment of a parasympathetic neural pathway are involved in reduction of infarct size.

Recently, Michelsen and colleagues have demonstrated that dialysate of human plasma from subjects who underwent either ischemic preconditioning or exercise preconditioning reduced infarct size in rabbit hearts, indicating that release of a humoral factor, contributes to the cardioprotective effects of ischemic and exercise preconditioning; however, these circulating substance(s) remain to be identified.

Future investigations will need to monitor heart rate, heart rate variability, and sympathetic nerve activity in order to more fully assess the role of the autonomic nervous system in mediating the sustained increases in SPP and systolic blood pressure reported in this initial study and focus on assessment of plasma samples during and following skin delivery COapplication. The D’OXYVA device is safe and can be administered at home. There are a lot of possibilities here and we are really excited about conducting future studies to determine what D’OXYVA may be able to provide to people with microvascular disease.

physician-recommended, easy to use daily

Why Use D'OXYVA?

Experts say D’OXYVA® can help patients find relief. Overwhelming medical data shows people with preexisting conditions, including diabetes may experience serious complications with COVID-19. D’OXYVA significantly helps people and their pets by gently and quickly spraying a patented and patent-pending ultra-purified, supersaturated solution on the skin surface to achieve major health benefits for well over 90% of users. Experts call D’OXYVA a game-changer biotech. “Studies with D’OXYVA have shown unmatched results in noninvasive wound care. Anyone with an underlying condition should know this option is available.” -Dr. Michael McGlamry

Reduce unwanted doctor visits, recommended
and ranked top by experts!

Leave a Reply

Your email address will not be published. Required fields are marked *